Efficacy of Tofacitinib in Juvenile Idiopathic Arthritis: A Systematic Review

Introduction: tofacitinib represents a promising therapeutic option for children with JIA, offering potent immunomodulation and disease remission in select patient populations. The expanding armamentarium of JAK inhibitors, including tofacitinib, provides clinicians with additional treatment options for patients refractory to conventional therapies or experiencing treatment failure.Material and methods: Data extraction was independently performed by two reviewers using a standardized form. Extracted data encompassed study characteristics (author, publication year, study design), participant demographics (age, gender), intervention details (tofacitinib dose, treatment duration), comparator(s), outcome measures (efficacy endpoints, adverse events), and results.Results: The pooled analysis of randomized controlled trials (RCTs) showed a significant reduction in disease activity scores post-tofacitinib treatment compared to placebo or conventional disease-modifying antirheumatic drugs (DMARDs) in pediatric patients with JIA. Notably, there was a marked decrease in the Juvenile Arthritis Disease Activity Score (JADAS) and the Childhood Health Assessment Questionnaire (CHAQ) scores, indicating improvements in disease activity and functional status, respectively.Conclusion: our systematic review provides robust evidence supporting the efficacy of tofacitinib as a valuable treatment option for children with JIA. Tofacitinib demonstrates significant improvements in disease activity, functional status, and clinical outcomes compared to conventional therapies or placebo.

کلیدواژه ها:

Tofacitinib ، Juvenile idiopathic arthritis ، Efficacy ، Systematic review